201 results about "Resistant bacteria" patented technology

The invention discloses a full D-type antibacterial peptide with high enzymolysis stability and broad-spectrum antibacterial activity and application thereof. The antibacterial peptide is obtained by sequentially and repeatedly arranging D-type tryptophan, D-type arginine and D-type lysine for four times and carrying out C-terminal amidation; the amino acid sequence of the gene is (D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-NH2, and is marked as DWRK-12. The antibacterial peptide shows broad-spectrum antibacterial activity and excellent stability, can effectively resist clinically separated multidrug resistant strains, and keeps high cell selectivity at the same time. Due to the characteristics, the antibacterial peptide has important application value in the aspect of developing novel antibacterial drugs, especially in the field of treatment of infection of multiple drug-resistant bacteria.

The invention discloses a polyketone compound derived from actinomycetes as well as a preparation method and application thereof, and relates to the technical field of microbial natural product mining and biological medicine, and the key point of the technical scheme is that the invention discloses a novel polyketone compound Strepactone derived from actinomycetes Streptomyces sp. DP0001, and the molecular formula of the novel polyketone compound Strepactone is C25H38O5. The compound is obtained through strain fermentation, ethyl acetate extraction and multi-step chromatographic purification, and the structure is identified through ESI-MS, 1H NMR and 13C NMR. Experiments show that Strepactone has an inhibition effect on staphylococcus aureus and methicillin-resistant staphylococcus aureus and has remarkable inhibition activity on human non-small cell lung cancer A549 cells, the half inhibitory concentration IC50 of the Strepactone is 5.36 mu M, and the Strepactone has no obvious cytotoxic activity on human embryo kidney cells 293T cells at the concentration of 30 mu M. The compound provided by the invention can be used for preparing anti-drug-resistant bacteria drugs and anti-human non-small cell lung cancer drugs, and also provides a structural basis for the development of novel antibacterial and anti-tumor leading drugs.

This invention relates to a 1,3,4-thiadiazole peptide deformylase inhibitor and its preparation and application. The structural formula is shown in formula (1): wherein, R 1 It is n-butyl or cyclopentylmethyl; R 2 The compounds are hydrogen-containing, straight-chain alkanes, cyclic alkanes, aromatic rings, substituted biphenyls, or heterocyclic rings. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention can effectively inhibit bacterial protein synthesis, thereby achieving sterilization. These compounds exhibit excellent inhibitory activity against Gram-positive drug-resistant bacteria, especially the clinically challenging methicillin-resistant Staphylococcus aureus (MRSA). In particular, some preferred compounds show inhibitory activity 4-8 times that of the control standards vancomycin and linezolid. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention also exhibit inhibitory activity against Gram-negative drug-resistant bacteria, especially against drug-resistant Acinetobacter baumannii, known as "superbugs," with an inhibitory activity reaching 0.5 μg / mL, far superior to vancomycin and linezolid.

The invention relates to the technical field of biological medicine, in particular to application of flufenamic acid in preparation of a polymyxin E antibacterial synergist. The invention discloses an application of flufenamic acid in preparation of a polymyxin E antibacterial synergist, the flufenamic acid has no obvious antibacterial effect on salmonella when being independently used, but the flufenamic acid and polymyxin E can enhance the antibacterial activity of the polymyxin E on the salmonella and reduce the use dosage of the polymyxin E when being jointly used in and out of an animal body, so that the antibacterial effect of the polymyxin E on the salmonella can be enhanced. The antibacterial activity of the polymyxin E on salmonella is enhanced, and the drug resistance of the polymyxin E is inhibited. Flurfenamic acid is approved to be used for other purposes as FDA, and when the flurfenamic acid is combined with polymyxin E, the flurfenamic acid has the characteristic of high safety, and meanwhile, the generation of the drug resistance of the polymyxin E drugs can be effectively avoided. The invention provides a basis for mining a new antibacterial prevention and control strategy for the polymyxin E drug-resistant bacteria.

This invention relates to a method for preparing medical nanozymes, the medical nanozymes themselves, their applications, and pharmaceuticals, belonging to the field of biomedicine. It addresses at least one of the following problems in existing technologies for treating deep tissue infections caused by drug-resistant bacteria: poor antibacterial and anti-biofilm effects, insufficient deep tissue penetration, lack of inflammation regulation and tissue repair functions, biosafety risks, and high material preparation costs. The preparation method includes: mixing rhodium trichloride, urea, and polyvinylpyrrolidone to obtain a mixture; subjecting the mixture to staged pyrolysis under inert gas protection to obtain a nitrogen-doped carbon-supported single-atom rhodium catalyst; and modifying the nitrogen-doped carbon-supported single-atom rhodium catalyst with polyethylene glycol. The medical nanozymes prepared by this invention achieve excellent antibacterial and anti-biofilm effects both in vivo and in vitro, can regulate the inflammatory microenvironment, promote tissue repair, exhibit good biocompatibility, and have strong tissue penetration ability.

Described herein is a synergistic combination comprising a quorum-sensing inhibitor and / or postbiotic metabolite and an antibiotic. Typically, the postbiotic metabolite comprises at least one peptide. Related compositions, uses, and methods are also described, including methods for resensitizing resistant bacteria to an antibiotic, and methods of treating antibiotic-resistant infections, such as methicillin-resistant Staphylococcus aureus (MRSA).

The invention discloses a Ti < 3 > C < 2 > T < x > MXene-GQD nano composite material as well as a preparation method and application thereof, and relates to the technical field of composite material preparation. The method comprises the following steps: dissolving LiF in a hydrochloric acid solution, and adding Ti3AlC2 powder to prepare a colloidal solution; the preparation method comprises the following steps: dissolving citric acid in deionized water, and then carrying out hydrothermal carbonization to prepare a GQD solution; and mixing the colloidal solution and the GQD solution, and stirring to obtain the nano composite material. According to the invention, the Ti3C2Tx MXene two-dimensional lamellar structure is utilized to stabilize the GQD nanoparticles, so that the GQD nanoparticles are uniformly dispersed and are not easy to agglomerate, and the long-term uniformity is ensured; by utilizing the photothermal effect of Ti3C2Tx MXene and the photodynamic effect of GQD, the dual photoresponse antibacterial efficiency is realized, the infection of drug-resistant bacteria can be efficiently inhibited, a non-antibiotic way is provided for treating the drug-resistant bacteria, and the infection problem and the related postoperative pain problem are effectively controlled in practice.

This application relates to the biomedical field and discloses a method for preparing a type I composite photosensitizer with both hydrogen sulfide detection capabilities and its uses. The invention synthesizes a triphenylamine derivative TPAB with an A-π-D-π-A conjugated structure using TPA-CHO and MN as monomers via a Schiff base reaction, and further incorporates Cu... 2+ By introducing TPAB molecules, a stable metal complex photosensitizer is formed through coordination bonds. This application presents the functional composite photosensitizer TPAB-Cu. 2+ Characterized primarily by the generation of type I ROS, it exhibits highly efficient photodynamic bactericidal activity in hypoxic environments infected with drug-resistant bacteria. Furthermore, this functional molecule can be used to detect hydrogen sulfide levels in the microenvironment of drug-resistant bacterial infections, enabling early warning and real-time monitoring of the treatment process. This solves the technical problems of strong oxygen dependence of photosensitizers and insufficient sensitivity and specificity in response to the microenvironment of drug-resistant bacterial infections in existing photodynamic therapies.

The application discloses a complex preparation containing bovine lactoferrin and lyticase and application thereof, and belongs to the technical field of biology. The preparation is composed of bovine lactoferrin and streptococcal lyticase, and both are prepared through a baculovirus-insect cell eukaryotic expression system. Researches show that the complex preparation has a significant synergistic antibacterial effect. The complex preparation not only can effectively inhibit a plurality of gram-positive bacteria, but also can overcome the limitation that single streptococcal lyticase has weak activity on gram-negative bacteria, and significantly enhances the inhibiting effect on escherichia coli and salmonella. Especially, the complex preparation still has clear in-vitro antibacterial activity on multi-drug resistant escherichia coli such as ciprofloxacin and doxycycline, thereby providing a new way for developing a new type of drug for resisting drug-resistant bacteria.

This invention discloses a method for preparing selenium-cuprous oxide-lithium saponite composite nanozymes from plant-derived complexes and their antibacterial applications, belonging to the fields of nanomaterials technology and antibacterial agents. The method includes the following steps: using peeled lithium saponite as a carrier, and utilizing a plant-derived complex formed from quinoa husk extract, aloe-emodin, and ascorbic acid as a reducing agent and stabilizer, the selenium-cuprous oxide-lithium saponite composite nanozyme is synthesized. The resulting composite nanozyme has a core-shell structure, with lithium saponite nanosheets as a carrier and uniformly distributed selenium-cuprous oxide nanoparticles on the surface. It exhibits excellent peroxidase-mimicking activity, catalyzing the generation of a large number of reactive oxygen species and disrupting bacterial cell structure. It shows significant antibacterial effects against various drug-resistant bacteria, and possesses good biocompatibility and environmental friendliness, showing broad application prospects in antibacterial therapy, wound dressings, and biomedical engineering.

This invention discloses a powder containing doxycycline hydrochloride and potassium clavulanate for aquaculture, its preparation method, and its application, belonging to the field of biotechnology. This invention combines doxycycline hydrochloride and potassium clavulanate to enhance the antibacterial ability of aquatic animals against drug-resistant bacteria, thereby better treating various diseases caused by drug-resistant bacteria in aquatic animals. Further experiments demonstrate that potassium clavulanate can significantly reduce bacterial resistance and enhance the antibacterial activity of doxycycline hydrochloride. The preparation of a composite powder using the combination of doxycycline hydrochloride and potassium clavulanate is simple, uses readily available raw materials, and is suitable for large-scale industrial production. Its application in the treatment of aquatic animal diseases, verified through challenge experiments, demonstrates the effectiveness of this composite powder in treating bacterial infections in aquatic animals. It has broad application prospects.

The present invention relates to a novel peptide derived from Hirudo nipponia, which has antimicrobial activity, antibiofilm activity, antibiotic sensitivity–enhancing activity, and anti-inflammatory activity. With antimicrobial activity, antibiofilm activity, antibiotic sensitivity–enhancing activity, and anti-inflammatory activity, the novel peptide derived from Hirudo nipponia according to the present invention can be advantageously applied as a material for various purposes in the pharmaceutical field, food field, cosmetic field, and agriculture and livestock industries. In addition, the novel antimicrobial peptide derived from Hirudo nipponia according to the present invention increases the sensitivity of antibiotics to multidrug-resistant bacteria, thereby markedly enhancing antimicrobial activity against multidrug-resistant bacteria when used in combination with antibiotics. Accordingly, a composition of the present invention comprising the peptide as an active ingredient can be advantageously used as a pharmaceutical composition for enhancing antibiotic sensitivity. In particular, the novel peptide of the present invention has very low hemolytic activity and cytotoxicity, and thus is safe for the human body. Moreover, the novel peptide of the present invention not only has excellent activity even under a high salt concentration, but also maintains activity even in a serum environment, thereby having high stability when applied in vivo.

The invention belongs to the technical field of microorganisms, and particularly discloses a bacterium-algae symbiotic system repairing preparation and a preparation method and application thereof. In particular to a bacterium-algae symbiotic system repairing preparation, the repairing preparation comprises acid-resistant microalgae and acid-resistant bacteria, the acid-resistant microalgae is chlamydomonas SAG 2486, and the acid-resistant bacteria comprise serratia liquefaciens AN41 and serratia JG-4-2. The invention discloses a bacterium-algae symbiotic system repairing preparation and a preparation method and application thereof, the bacterium-algae symbiotic system repairing preparation naturally improves soil through biological metabolism, and avoids the risks of soil hardening, ion imbalance, secondary salinization and the like caused by a chemical acid regulating agent.

The invention belongs to the technical field of environmental functional material preparation and water pollution treatment, and particularly relates to a cyclodextrin-based metal organic framework porous aerogel material and a preparation method thereof. The method comprises the following steps: 1) modifying cyclodextrin by using a silane coupling agent to obtain silanized cyclodextrin marked as A-CD; 2) preparing a physical composite material marked as A-CD-MOF / PNC by using A-CD, a metal salt and a chlorine-containing organic cross-linking agent as raw materials through a co-crystallization method; and 3) under the action of a catalyst, carrying out chemical reaction on the A-CD-MOF / PNC and a chlorine-containing organic cross-linking agent to prepare a chemical composite material, namely the cyclodextrin-based metal organic framework porous aerogel material. The material has the inclusion effect of cyclodextrin molecules, the amino active sites of the amino silane coupling agent and the stable heterocyclic structure of PNC, and synergistic removal of ciprofloxacin and drug-resistant bacteria is achieved.

This invention relates to the field of bacterial infection treatment technology, and discloses an enzyme-responsive probe, its preparation method, and its applications. The probe of this invention constructs an enzyme-responsive "prodrug" structure by introducing cephalosporin derivative linker units that can be specifically cleaved by β-lactamases onto a hemicyanine optical framework. This structure remains optically and therapeutically inert in normal tissues, but is selectively activated at the site of infection by drug-resistant bacteria. When the probe contacts multidrug-resistant bacteria that overexpress β-lactamases, the linker units undergo enzymatic cleavage, releasing hemicyanine active molecules with near-infrared fluorescence emission and highly efficient photothermal conversion capabilities, achieving high-contrast fluorescence imaging and controllable photothermal sterilization of the infection focus. The probe of this invention has a simple synthetic route, mild conditions, and reliable purification methods, making it suitable for large-scale preparation, especially for the precise diagnosis and targeted photothermal synergistic treatment of superficial tissue infections such as bacterial keratitis.

The application discloses an N-(3-cyclobutyrolactone)-4-nitrophenyl butyryl amide and amikacin composition and application of the composition in treating chronic infection of drug-resistant bacteria. After the N-(3-cyclobutyrolactone)-4-nitrophenyl butyryl amide and the amikacin are combined, not only the sensitivity of pseudomonas aeruginosa to the amikacin can be obviously increased, but also the formation amount of the pseudomonas aeruginosa biofilm can be greatly reduced, so that the composition can be applied to preventing and treating chronic infection of drug-resistant pseudomonas aeruginosa.

The invention discloses a PAM-limitation-free SNM detection method based on a CRISPR / Cas12a system and application of the PAM-limitation-free SNM detection method. The method comprises the steps that genome DNA is extracted from a to-be-detected sample and normal bacteria, a common gene of drug-resistant bacteria and the normal bacteria serves as a target gene to design a primer, and a to-be-detected target ssDNA chain is obtained through aPCR amplification; designing corresponding crRNA according to a target ssDNA chain, designing a Blocker chain complementary with a nucleic acid sequence of a non-seed region of a Spacer region of the crRNA, and combining the crRNA and the Blocker chain to obtain engineered crRNA; designing a tool long chain complementary with the nucleic acid sequence of the target ssDNA chain; designing a tool short chain complementary with the tool long chain; combining the tool long chain and the tool short chain with the target ssDNA chain to obtain a tool target heterodouble chain; and a Cas12a / CRISPR system is coupled to detect whether SNM occurs or not. The method disclosed by the invention is good in specificity and low in detection limit, and can be suitable for instant detection of various drug-resistant pathogenic microorganisms.

The application discloses a chimeric endolysin Lys009-Lys009CBD and engineering and application thereof, and belongs to the field of genetic engineering and protein engineering. The application constructs a chimeric endolysin Lys009-Lys009CBD with high activity, and the peptidoglycan hydrolysis activity of the chimeric endolysin Lys009-Lys009CBD on Pseudomonas aeruginosa is 5.30 times that of natural endolysin Lys009 and 27.98 times that of hen egg white lysozyme HEWL. A transmembrane peptide P81417 is further fused to perform transmembrane modification, and an engineering endolysin P81417-Lys009-Lys009CBD is obtained. The engineering endolysin can efficiently lyse Pseudomonas aeruginosa, Acinetobacter baumannii and the like, and has excellent thermal stability. The application enriches the resource library of high-activity endolysins, provides important experimental basis and technical support for developing an anti-drug-resistant bacteria treatment strategy, and also provides a new selection for clinical treatment of multiple drug-resistant bacteria infection.

Disclosed herein are methods and compositions related to probiotic formulas. These formulas comprise the bacterial strain Lactobacillus crispatus WZ-12 or a derivative thereof. Other strains which can be included in the composition include, but are not limited to, Lactobacillus salivarius 1-14, or Lactobacillus reuteri 2-2, and derivatives thereof. These compositions can be used in a variety of methods to treat and / or ameliorate diseases, such as colonization of antibiotic-resistant bacteria in the host organism. Also disclosed herein are methods of treating those subjects in need thereof by administering the compositions disclosed herein.

The application discloses a decapeptide derivative, a preparation method and application thereof. The application protects a Paenibacillus polymyxa, that is, Paenibacillus polymyxa CPCC 101223, and the preservation registration number is CGMCC No. 22854. The application also protects a preparation method of the compound, which comprises the following steps: fermenting and culturing the Paenibacillus polymyxa CPCC 101223 to obtain the compound. The application also protects application of the compound or a pharmaceutically acceptable salt thereof in preparation of a bacterial inhibitor. The application also protects the bacterial inhibitor, which contains the compound or the pharmaceutically acceptable salt thereof. The compound of the application is derived from the Paenibacillus polymyxa, has a simple preparation process, has good activity against gram-negative drug-resistant bacteria, provides a theoretical basis for clarifying the structure-activity relationship of the decapeptide antibacterial activity, and is suitable for research on a gram-negative drug-resistant bacteria leading compound or preparation of a gram-negative drug-resistant bacteria drug.

The application discloses a method for repairing heavy metal contaminated soil by combining plants and microorganisms, and comprises the following steps: planting alfalfa seeds in heavy metal contaminated soil; inoculating lead and zinc copper resistant bacteria L1 into the heavy metal contaminated soil after 30 days when the seeds germinate; and harvesting the alfalfa after the growth period of the alfalfa ends. The application has a very obvious effect on adsorbing lead, zinc and copper heavy metals in the soil. The plant raw material is low in cost, the preparation process is simple and easy to operate, and the bacterial liquid is easy to culture. The application has small investment for removing heavy metals and no secondary pollution.

This invention provides modified antimicrobial peptides, belonging to the field of antimicrobial peptide technology. The modified antimicrobial peptides include at least one of a first, second, third, fourth, fifth, and sixth antimicrobial peptide; the amino acid sequences of the first, second, third, fourth, fifth, and sixth antimicrobial peptides are shown sequentially as SEQ ID NO.1 to SEQ ID NO.6. Based on prevotellin-2, the modified antimicrobial peptides were obtained by reducing negatively charged amino acids, increasing positively charged amino acids, introducing hydrophobic amino acids, adjusting or deleting amino acid sequences, and optimizing the peptide structure. In vitro minimum inhibitory concentration (MIC) determination showed that, compared with the initial peptide, the modified antimicrobial peptides exhibited significantly enhanced antimicrobial activity against bacteria and fungi, and also showed significant bactericidal activity against clinically resistant bacteria.

The application belongs to the field of genetic engineering, and specifically discloses a new sterilization method for realizing precise and efficient sterilization of drug-resistant bacteria by combining CRISPR and a toxin-antitoxin element coupled therewith. The application innovatively uses the guardian RNA element CreTA of CRISPR to improve the stability of the CRISPR-Cas element in the process of sterilizing drug-resistant bacteria, realizes the double sterilization effect of CRISPR and TA, and thus effectively improves the efficiency of the CRISPR sterilization technology in practical application.

The livestock farm excrement treatment device comprises a shell, an inner cavity of the shell is a fermentation bin, an excrement collecting tank, a bacteriophage reaction chamber, an ultraviolet disinfection chamber, an exhaust purification module, a control module and a sensor group are arranged in the fermentation bin, the excrement collecting tank is arranged on the left side wall of the shell, and the bacteriophage reaction chamber is arranged on the left side wall of the shell. The shell is communicated with an inlet of the bacteriophage reaction chamber through a pipeline, an outlet of the bacteriophage reaction chamber is connected with the ultraviolet disinfection chamber through a pipeline, the ultraviolet disinfection chamber is communicated with the exhaust purification module arranged on the right side wall of the shell through a pipeline, the control module is arranged on the upper wall in the shell, and the sensor group is distributed on the ultraviolet disinfection chamber and the control module. According to the utility model, the bacteriophage is introduced into an excrement treatment system, so that pathogenic bacteria in excrement are specifically split, and the problems of poor animal excrement sterilization effect, limited drug-resistant bacterium inactivation effect, high possibility of generating harmful byproducts and the like in the prior art are solved.

This invention relates to an oxobenzohexacyclic borate ester compound, its preparation method, and its uses, belonging to the pharmaceutical field. The derivatives of this invention are compounds represented by Formula I, or their salts, conformational isomers, or optical isomers. The oxobenzohexacyclic borate ester derivatives provided by this invention exhibit good, broad-spectrum inhibitory activity against clinically common metallo-β-lactamases (MBL) and serine β-lactamases (SBL), and show good antibacterial activity against various drug-resistant bacteria when used in combination with the β-lactam antibiotic meropenem. Therefore, the series of derivatives provided by this invention have great potential in the preparation of dual broad-spectrum inhibitors of MBL and SBL and in drugs to overcome β-lactam antibiotic-resistant bacteria. Formula I.

The invention relates to the technical field of biological medicine, in particular to a cell membrane labeled molecular probe, a preparation method and application of the cell membrane labeled molecular probe in the imaging direction of drug-resistant bacteria, and the preparation method of the cell membrane labeled molecular probe comprises the following steps: step 1, mixing N, N '-carbonyldiimidazole and nonanoic acid for reaction to obtain active ester, tert-butyl (2-aminoethyl) carbamate is added for a reaction, and tert-butyl (2-nonanoylamido ethyl) carbamate is obtained; step 2, the tert-butyl (2-nonanoylamido ethyl) carbamate and trifluoroacetic acid are subjected to a reaction, and N-(2-aminoethyl) nonanoylamides are obtained; 3, at the room temperature, fluorescein isothiocyanate ester, N-(2-aminoethyl) nonanamide and triethylamine are subjected to a reaction, and the molecular probe is obtained. The molecular probe prepared by the invention has a stable chemical structure, is not easy to degrade or decompose in a physiological environment, can maintain long-time fluorescence performance, and is suitable for long-time cell membrane marking and imaging experiments.

The invention belongs to the technical field of prevention and control of drug-resistant bacteria, and particularly discloses a composite bactericidal composition and application thereof in preparation of a reagent for killing aeromonas hydrophila oxytetracycline drug-resistant strains. The minimum inhibitory concentration of the epsilon-polylysine to an aeromonas hydrophila oxytetracycline drug-resistant strain is as low as 3.125 g / mL. Meanwhile, the sterilization mechanism of the epsilon-polylysine on aeromonas hydrophila oxytetracycline drug-resistant strains is discussed through metabonomics research. On the basis, the application finds that various exogenous small molecule metabolites such as 2-phenylacetamide and the like are combined with epsilon-polylysine for use, so that the absorption of drug-resistant bacteria on epsilon-polylysine can be promoted, the sterilization effect of the epsilon-polylysine is effectively enhanced, and the problem of drug resistance of bacteria is solved. Therefore, when the epsilon-polylysine and the exogenous small molecule metabolite are jointly applied, compared with the existing single antibiotic therapy, the epsilon-polylysine has higher activity and better safety and operability in preparation of the reagent for resisting the aeromonas hydrophila oxytetracycline drug-resistant strain.

The invention relates to the technical field of biology, in particular to a broad-spectrum bacteriophage lyase mutant, an extraction and purification reagent and a kit. The invention provides a broad-spectrum bacteriophage lyase mutant, an extraction and purification reagent and a kit. A broad-spectrum bacteriophage lyase mutant nucleic acid release liquid containing protein with an amino acid sequence as shown in SEQ ID NO: 1 is adopted; the compound can efficiently act on two important clinical drug-resistant bacteria, namely methicillin-resistant staphylococcus aureus MRSA and vancomycin-resistant enterococcus VRE, at the same time. Through unique molecular design and preparation process optimization, the lyase shows excellent synchronous wall breaking capacity, cell wall destruction can be completed in an extremely short time, and the nucleic acid release efficiency is remarkably superior to that of a traditional method.

The invention discloses application of chlorpromazine hydrochloride in preparation of an acinetobacter baumannii infection resisting medicine, and belongs to the technical field of biological medicine. The invention proves that when the chlorpromazine hydrochloride is independently used, the growth of the acinetobacter baumannii can be inhibited, wherein the acinetobacter baumannii comprises colistin-resistant acinetobacter baumannii; meanwhile, chlorpromazine hydrochloride can cooperate with colistin to play a role in resisting acinetobacter baumannii, so that infection caused by colistin-resistant acinetobacter baumannii is treated. When a certain concentration of chlorpromazine hydrochloride and colistin are combined for use, more than 50% of colistin-resistant acinetobacter baumannii is killed within 4 hours, and the survival rate is lower than 1%, which proves that chlorpromazine hydrochloride and colistin have a synergistic effect. The chlorpromazine hydrochloride and the colistin are combined for use, so that the chlorpromazine hydrochloride and the colistin can be used for resisting colistin drug-resistant pathogens and treating diseases caused by colistin drug-resistant bacteria infection, and meanwhile, the evolution of colistin drug resistance can also be prevented.

The utility model relates to an antibiotic degrading bacterium inoculant applying and feeding device which comprises a reaction barrel, a rotating part is arranged at the top of the reaction barrel, a circular ring part is clamped at the top of the rotating part, a filtering membrane bag is arranged in an inner cavity of the reaction barrel, and the filtering membrane bag has the filtering characteristic that water and bacteria are not permeated. And the edge opening of the filter membrane bag is fixed at the top of the rotating part through a ring part. According to the utility model, the stirring of the stirring blades can fully stimulate the efficacy of a degrading bacterium agent, so as to ensure that the pollution of treated wastewater to water ecology can be greatly reduced; meanwhile, a degrading bacterium agent can be filtered and collected by virtue of the filtering membrane bag, so that the problem that the water ecology is polluted by drug-resistant bacteria and antibiotic resistance genes due to the fact that the degrading bacteria and degrading genes carried by the degrading bacteria are discharged along with the liquid is effectively avoided. The degradation of novel pollutant antibiotics is completed, the diffusion of drug-resistant bacteria and antibiotic resistance genes carried by the drug-resistant bacteria is limited, and the ecological environment of a water body is comprehensively guaranteed.